Status:

TERMINATED

Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting

Lead Sponsor:

Ural State Medical University

Collaborating Sponsors:

Ural Institute of Cardiology

De Haar Research Foundation

Conditions:

Coronary Artery Disease

Atherosclerosis

Eligibility:

All Genders

45-65 years

Phase:

PHASE1

Brief Summary

Intensive therapy with rosuvastatin 40 mg and ApoA-I Milano reduces the total atheroma volume (TAV) up to 6.38 or 14.1 mm3 respectively. Our previous bench studies PLASMONICS and NANOM First-in-Man tr...

Detailed Description

Nanoparticles (NPs) are quite safe for an organism but entire kinetics is mostly unknown. The most dangerous approach with lowest level of efficacy and safety is a delivery of NPs with microbubbles. S...

Eligibility Criteria

Inclusion

  • Multivessel coronary artery disease without indications for CABG
  • Stable angina with indications for preventive PCI
  • NSTEMI (primary PCI and late comers) \<=\> 12 hr
  • STEMI with kept EF\>50% (all comers)
  • Rescue PCI
  • Vessel size between 2.3-4.0 mm
  • NYHA II-III functional class of HF
  • De novo treatment = no history of PCI or CABG
  • Atherosclerosis of proximal left anterior descending artery \<50% stenosis
  • Treated hypertension
  • Signed written informed consent

Exclusion

  • History of MI
  • History of CABG or PCI
  • Indications for CABG
  • Contraindications for CABG, PCI
  • History of unstable angina, coronary artery syndrome
  • History of arrhythmias
  • History of stroke
  • NYHA I, IV functional class of HF
  • Diabetes (fasting glucose \> 7.0 mM/L)
  • Untreated hypertension
  • Asthma
  • Participation to any drug-investigations during previous 60 days
  • Pregnancy
  • Intolerance to any limus drugs, aspirin, clopidogrel, aspirin, metals and polymers of stent and nanoparticles
  • Need for chronic treatment with anti-vitamin K drugs
  • Impossibility of clinical follow-up

Key Trial Info

Start Date :

December 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2012

Estimated Enrollment :

62 Patients enrolled

Trial Details

Trial ID

NCT01436123

Start Date

December 1 2010

End Date

October 1 2012

Last Update

May 19 2015

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

De Haar Research Foundation

Rotterdam, South Holland, Netherlands, 3071PR

2

Ural Center of Modern Nanotechnologies, Institute of Natural Sciences, Ural Federal University

Yekaterinburg, Sverdlovsk Oblast, Russia, 620000

3

Ural Institute of Cardiology

Yekaterinburg, Sverdlovsk Oblast, Russia, 620144